Finally, it was concluded that the OLFML2A gene, as a molecular indicator, can be involved in the diagnosis, prognosis, and immune process of AML and has the potential to be a reliable prognostic assessment indicator W and a potential therapeutic boot point for AML patients. Here, OLFML2A is linked to acute myeloid leukemia.